- Home
- PRGO vs ACLX Comparison
PRGO vs ACLX Comparison
Compare PRGO & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGO | ACLX |
|---|---|---|
| Founded | 1887 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 4.2B |
| IPO Year | 1991 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PRGO | ACLX |
|---|---|---|
| Price | $13.15 | $72.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $22.50 | ★ $115.71 |
| AVG Volume (30 Days) | ★ 3.7M | 1.4M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,281,800,000.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $302.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.17 | $47.86 |
| 52 Week High | $30.93 | $94.07 |
Technical Indicators
Market Signals| Indicator | PRGO | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 33.32 | 40.25 |
| Support Level | $12.93 | $68.64 |
| Resistance Level | $13.63 | $73.98 |
| Average True Range (ATR) | 0.43 | 5.77 |
| MACD | 0.29 | -0.14 |
| Stochastic Oscillator | 44.25 | 21.95 |
Price Performance
Historical ComparisonAbout PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.